BRD4 inhibition enhances azacitidine efficacy in acute myeloid leukemia and myelodysplastic syndromes

BRD4 inhibition enhances azacitidine efficacy in acute myeloid leukemia and myelodysplastic syndromes

Fernando Vieira Pericole, Mariana Lazarini, Luciana Bueno de Paiva, Adriana da Silva Santos Duarte, Karla Priscila Vieira Ferro, Fernanda Soares Niemann, Fernanda Marconi Roversi, Sara Teresinha Olalla Saad

ARTIGO

Inglês

Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell-based disorders characterized by ineffective hematopoiesis, increased genomic instability and a tendency to progress toward acute myeloid leukemia (AML). MDS and AML cells present genetic and epigenetic abnormalities and, due to the...

FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP

CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQ

aberto

BRD4 inhibition enhances azacitidine efficacy in acute myeloid leukemia and myelodysplastic syndromes

Fernando Vieira Pericole, Mariana Lazarini, Luciana Bueno de Paiva, Adriana da Silva Santos Duarte, Karla Priscila Vieira Ferro, Fernanda Soares Niemann, Fernanda Marconi Roversi, Sara Teresinha Olalla Saad


										

BRD4 inhibition enhances azacitidine efficacy in acute myeloid leukemia and myelodysplastic syndromes

Fernando Vieira Pericole, Mariana Lazarini, Luciana Bueno de Paiva, Adriana da Silva Santos Duarte, Karla Priscila Vieira Ferro, Fernanda Soares Niemann, Fernanda Marconi Roversi, Sara Teresinha Olalla Saad

    Fontes

    Frontiers in oncology

    Vol. 9 (Jan., 2019), n. art. 16